OxTalks is Changing
On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Biomarker driven immune therapy for colorectal cancer.
We have demonstrated that histone deacetylase inhibitors (HDACi) can reinstate immune reactivity in colorectal cancer cells by upregulation of elements of the machinery of immune presentation, including MHC class1. We went on to show that the combination of an HDACi with an immune checkpoint inhibitor delivered synergistic anticancer effects in a syngeneic colorectal cancer (CRC) mouse model. We have performed a clinical trial to test this hypothesis in patients with advanced, refractory CRC with positive results. We have adapted our AI/digital pathology programme to develop a biomarker to select CRC patients who are more likely to benefit from this combination immunotherapy and plan to incorporate this into a prospective clinical trial.
Date:
1 March 2023, 12:00
Venue:
John Radcliffe Academic, Headington OX3 9DU
Venue Details:
Conference Room, Academic Centre, Level 3, JR Hospital
Speaker:
Prof David Kerr (Nuffield Division of Clinical Laboratory Sciences, Oxford)
Organising department:
Nuffield Division of Clinical Laboratory Sciences
Organiser:
Tina Garland (University of Oxford)
Organiser contact email address:
tina.garland@ndcls.ox.ac.uk
Booking required?:
Not required
Audience:
Members of the University only
Editor:
Tina Garland
